HD Visual Learning
HD Visual Learning
Personalizing Treatment Across Cutaneous Malignancies
Shared Decision-Making in Oncology
UV Exposure and Basal Cell Carcinoma: Genetic Mutations and Immune Suppression
Pathogenesis of Basal Cell Carcinoma (BCC)
Immunology and the Hedgehog Pathway in Basal Cell Carcinoma (BCC)
Depiction of the anti-cancer mechanism of action of Trop-2 antibody-drug conjugates in breast cancer
*Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Shared Decision-Making in Oncology
Understanding Cell-free DNA (cfDNA)
*Supported by an educational grant from GRAIL, Inc.
Cancer Screening and Early Dection Test Accuracy
*Supported by an educational grant from GRAIL, Inc.
Understanding the Underlying Science of Current Cancer Screening
*Supported by an educational grant from GRAIL, Inc.
Discussing the Results of a Multicancer Early Detection Test
*Supported by an educational grant from GRAIL, Inc.
ICIs: Primary & Micrometastatic Disease
Tumorigenesis Cutaneous Squamous Cell Carcinoma (cSCC)
Personalizing Treatment Across Cutaneous Malignancies
Shared Decision-Making in Oncology
Immune Dysfunction in Cutaneous Squamous Cell Carcinoma (cSCC)
Shared Decision-Making in Oncology
HER2 Expression in Cancer
*Supported by an independent medical educational grant from Jazz Pharmaceuticals.
Gastric Cancer – Understanding anti-tumor effects and monitoring for adverse events
*Supported by an educational grant from Lilly.
Angiogenesis Overview
*Supported by an educational grant from Lilly.
Shared Decision-Making in Oncology
The Complement SystemÂ
*Supported by an educational grant from Novartis Pharmaceuticals Corporation.
PD1 and CTLA-4 Immune Checkpoints
Novel Immune Targets in Solid and Liquid Tumors
Personalizing Treatment Across Cutaneous Malignancies
Shared Decision-Making in Oncology
Mechanistic Features of Bispecific Antibodies for Relapsed/Refractory NHL
Managing Adverse Events Associated with Bispecific Antibodies
Shared Decision-Making in Oncology
The Role of Antibody Drug Conjugates in B-Cell Lymphomas *Supported by an educational grant from Genentech, a member of the Roche Group.
Understanding the Rationale for Bispecific Antibody Threapy in Relapsed/Refractory B-Cell Lymphomas *Supported by an educational grant from Genentech, a member of the Roche Group.
Considering ICI Therapeutic Combinations in Advanced Melanoma
Visualizing pathophysiologic processes
Personalizing Treatment Across Cutaneous Malignancies
Shared Decision-Making in Oncology
Reviewing the Pathophysiology of Melanoma
Developments of PD-L1 and LAG3 Combinations in Advanced Melanoma
Mechanisms of Bispecific Antibodies in Multiple Myeloma
Managing CRS and ICANS with Bispecific Antibodies
Shared Decision-Making in Oncology
Mechanisms of Resistance in Multiple Myeloma
Mechanisms of Therapies in Later-Line Multiple Myeloma Management *Supported by an educational grant from GlaxoSmithKline.
Rationale for ICIs in patients without targetable mutations, particularly patients with squamous cell NSCLC
Complimentary anti-tumor mechanisms of chemotherapeutics and ICIs
MOA: Evaluating the mechanisms of checkpoint inhibition in NSCLC and relevant adverse events
Shared Decision-Making in Oncology
Mechanisms of HER2 Activation in NSCLC *Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Adverse Events Associated With HER2-Directed ADCs for Advanced NSCLC: Presentation & Management *Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Role of HER3 in EGFR-TKI resistance in Non-Small Cell Lung Cancer (NSCLC) *Supported by an educational grant from Daiichi Sankyo.
TROP2 Cell-Aurface Antigen in Tumors and Tumorgenesis *Supported by an educational grant from Daiichi Sankyo.
Frequent adverse events associated with Trop-2 antibody-drug conjugate therapy
*Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.
MOAs of HER2-directed ADCs for HER2-expressing solid tumors
*Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Development of AEs associated with the use of ADCs
*Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Â
Management of Recurrent Stage 2 cSCC and Rationale for Treatment
Management Pearls for Treatment of Multiple Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Treatment Strategies for Relapsed/Refractory Multiple Myeloma
NSCLC – Shared Decision Making Case Study
Myeloma BsAb iAR
Dive into immersive, case-based learning on evolving treatment strategies in multiple myeloma.This augmented reality experience is designed for hematology/oncology clinicians and provides highly interactive exploration of real-world decision-making in relapsed/refractory multiple myeloma (RRMM). Through two detailed patient cases, learners examine treatment sequencing, bispecific antibody (BsAb) integration, and toxicity management in accordance with clinical practice guidelines. Simply launch the app and point your device at a flat surface to begin. The AR experience places engaging, expert-informed content directly into the learner’s environment, supporting dynamic and personalized knowledge retention.
Shaping the Future of NMSC
This program discusses the management of NMSC
Non-melanoma skin cancers (NMSCs), including basal cell carcinoma and cutaneous squamous cell carcinoma, are typically managed with Mohs micrographic surgery, but advanced cases may require alternative approaches due to inoperability or progression. The immunogenicity of NMSCs makes them strong candidates for immune checkpoint inhibitor therapy, with agents like cemiplimab and pembrolizumab demonstrating favorable efficacy and tolerability. Emerging strategies, including neoadjuvant and intralesional immunotherapy, are under investigation to enhance tumor response prior to or in place of surgery. Continued development of these immunotherapeutic approaches offers the potential to improve outcomes in patient care.
The ENCOMPASS Experience: DYNAMIC CARE DISCUSSIONS: Incorporating Bispecific Antibody Therapies into Patient-Centric Treatment Plans for RELAPSED/REFRACTORY NHL
Virtual Booth
The ASH 2025 ENCOMPASS Experience: Advancing BCMA-Directed Bispecific Antibodies in r/rMM: Mechanistic Rationale, Clinical Evidence & Strategies to Optimize Patient Outcomes
Virtual Booth
TANDEM 2026: FROM FIRST-LINE FAILURE TO TARGETED CARE: Expert Guidance on Optimized Treatment Selection & Multidisciplinary Care for Patients with cGVHD *Supported by an independent medical education grant from Sanofi US.
Virtual Booth
TARGETING HER2: Updates on New and Emerging Treatment Approaches in Biliary Tract Cancers and Gastroesophageal Adenocarcinoma *Supported by an independent medical education grant from Jazz Pharmaceuticals.
Virtual BoothÂ